Literature DB >> 4739330

Androgenic therapy for advanced breast cancer in women. A report of the cooperative breast cancer group.

I S Goldenberg, N Waters, R S Ravdin, F J Ansfield, A Segaloff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4739330

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  12 in total

1.  Women and health bookshelf.

Authors:  J B Sprague
Journal:  Am J Public Health       Date:  1975-07       Impact factor: 9.308

Review 2.  Anti-estrogens and aromatase inhibitors: tamoxifen and testolactone.

Authors:  F Sciarra
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

3.  Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.

Authors:  T R Rebbeck; P W Kantoff; K Krithivas; S Neuhausen; M A Blackwood; A K Godwin; M B Daly; S A Narod; J E Garber; H T Lynch; B L Weber; M Brown
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

Review 4.  Targeting the androgen receptor in triple-negative breast cancer.

Authors:  Ayca Gucalp; Tiffany A Traina
Journal:  Curr Probl Cancer       Date:  2016-09-20       Impact factor: 3.187

5.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 6.  Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.

Authors:  E Samojlik; J D Veldhuis; S A Wells; R J Santen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

Review 7.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Androgen receptor as a targeted therapy for breast cancer.

Authors:  Joseph P Garay; Ben H Park
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

9.  A new hormonal therapy for estrogen receptor-negative breast cancer.

Authors:  Chelsea Hardin; Rodney Pommier; Kristine Calhoun; Patrick Muller; Terisa Jackson; SuEllen Pommier
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.

Authors:  M Dowsett; S J Santner; R J Santen; S L Jeffcoate; I E Smith
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.